Bridgebio Pharma, Inc. · NASDAQ:BBIO
Kumar Neil sold 44,980 Bridgebio Pharma, Inc. shares (Form 4)
Traded Aug 18 to Aug 19, 2026 · Filed Aug 20, 2026
From Aug 18 to Aug 19, 2026, Kumar Neil (Director, Chief Executive Officer) sold 44,980 Bridgebio Pharma, Inc. shares at an average US$82.86 for US$3.73M under a trading plan, leaving 505,686 shares. Filed Aug 20, 2026 (Form 4).
- Sold
- 44,980 shares
- Price
- US$82.86 average (US$81.15 to US$85.65)
- Value
- US$3.73M
- Holding after
- 505,686 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chief Executive Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Common Stock | Sale | 1,900 | US$81.15 | 276,407 | Direct |
| Aug 18, 2026 | Common Stock | Sale | 17,279 | US$82.21 | 259,128 | Direct |
| Aug 18, 2026 | Common Stock | Sale | 14,602 | US$82.99 | 244,526 | Direct |
| Aug 18, 2026 | Common Stock | Sale | 1,199 | US$83.77 | 243,327 | Direct |
| Aug 19, 2026 | Common Stock | Sale | 8,100 | US$83.86 | 507,586 | Indirect |
| Aug 19, 2026 | Common Stock | Sale | 1,800 | US$84.69 | 505,786 | Indirect |
| Aug 19, 2026 | Common Stock | Sale | 100 | US$85.65 | 505,686 | Indirect |
Source
Related
- Bridgebio Pharma, Inc.
- Kumar Neil
- Bridgebio Pharma, Inc. shareholders
- Form 4 · Kumar Neil · Sep 21, 2026
- Form 4 · Kumar Neil · Aug 18, 2026
- Form 4 · Kumar Neil · Jun 8, 2026
- Form 4 · Kumar Neil · May 26, 2026
- Form 4 · Kumar Neil · May 19, 2026
- Form 4 · Trimarchi Thomas · Aug 18, 2026
- Form 4 · Apuli Maricel · Aug 18, 2026
- Schedule 13D/A · KKR Genetic Disorder L.P. · Aug 17, 2026
- Form 4 · Apuli Maricel · Aug 3, 2026
- Schedule 13G/A · Farallon Capital Management, L.L.C. · Aug 3, 2026